Payment overview · 2025
General Payments
$177.97
9 reported records · 7 companies
Healthcare provider profile · identity verified
Malaz Alatassi, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · SHELBY TOWNSHIP, MI · NPI 1023069770
Verified facts
What the public records show
CMS Open Payments records show Malaz Alatassi, M.D. received $177.97 in general payments during 2025 across 9 reported records.
Otsuka America Pharmaceutical, Inc. accounted for 36.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Rexulti, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Lumigan by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 116 claims for Myrbetriq by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 376 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Trulicity by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Nuedexta by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Rexulti by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $65.02 | 36.5% | 3 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $32.84 | 18.4% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $18.35 | 10.3% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $17.34 | 9.7% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $15.08 | 8.5% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $14.81 | 8.3% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $14.53 | 8.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $177.97 | 9 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $65.02 | 3 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $32.84 | 1 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $18.35 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $17.34 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $15.08 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $15.08 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $14.81 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $14.53 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 37 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 71 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
116 | 13 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
19 | 19 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
71 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
376 | 59 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
46 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1554 | 252 |
| Levothyroxine Sodium | Levothyroxine Sodium | 1258 | 175 |
| Furosemide | Furosemide | 1054 | 183 |
| Quetiapine Fumarate | Quetiapine Fumarate | 826 | 102 |
| Eliquis | Apixaban | 816 | 121 |
| Omeprazole | Omeprazole | 792 | 150 |
| Metoprolol Succinate | Metoprolol Succinate | 750 | 134 |
| Losartan Potassium | Losartan Potassium | 684 | 125 |
| Donepezil Hcl | Donepezil Hcl | 655 | 83 |
| Potassium Chloride | Potassium Chloride | 639 | 107 |
| Tamsulosin Hcl | Tamsulosin Hcl | 621 | 93 |
| Amlodipine Besylate | Amlodipine Besylate | 531 | 111 |
| Memantine Hcl | Memantine Hcl | 499 | 76 |
| Trazodone Hcl | Trazodone Hcl | 498 | 88 |
| Mirtazapine | Mirtazapine | 489 | 84 |
| Sertraline Hcl | Sertraline Hcl | 474 | 69 |
| Metoprolol Tartrate | Metoprolol Tartrate | 451 | 90 |
| Escitalopram Oxalate | Escitalopram Oxalate | 450 | 60 |
| Gabapentin | Gabapentin | 428 | 82 |
| Lisinopril | Lisinopril | 415 | 77 |
| Jardiance | Empagliflozin | 376 | 59 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 367 | 56 |
| Clopidogrel | Clopidogrel Bisulfate | 366 | 65 |
| Finasteride | Finasteride | 357 | 54 |
| Pantoprazole Sodium | Pantoprazole Sodium | 354 | 67 |
| Famotidine | Famotidine | 347 | 68 |
| Simvastatin | Simvastatin | 299 | 42 |
| Hydralazine Hcl | Hydralazine Hcl | 278 | 65 |
| Pravastatin Sodium | Pravastatin Sodium | 278 | 33 |
| Hydrochlorothiazide | Hydrochlorothiazide | 275 | 43 |
| Metformin Hcl | Metformin Hcl | 272 | 59 |
| Carvedilol | Carvedilol | 264 | 44 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 200 | 41 |
| Duloxetine Hcl | Duloxetine Hcl | 195 | 30 |
| Allopurinol | Allopurinol | 191 | 38 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 187 | 65 |
| Fluoxetine Hcl | Fluoxetine Hcl | 183 | 24 |
| Alprazolam | Alprazolam | 175 | 49 |
| Xarelto | Rivaroxaban | 173 | 26 |
| Bumetanide | Bumetanide | 167 | 32 |
| Lorazepam | Lorazepam | 165 | 36 |
| Latanoprost | Latanoprost | 164 | 31 |
| Midodrine Hcl | Midodrine Hcl | 161 | 36 |
| Spironolactone | Spironolactone | 161 | 33 |
| Farxiga | Dapagliflozin Propanediol | 158 | 33 |
| Tramadol Hcl | Tramadol Hcl | 156 | 42 |
| Risperidone | Risperidone | 143 | 26 |
| Alendronate Sodium | Alendronate Sodium | 142 | 16 |
| Levetiracetam | Levetiracetam | 138 | 24 |
| Fluticasone Propionate | Fluticasone Propionate | 135 | 46 |
| Montelukast Sodium | Montelukast Sodium | 130 | 21 |
| Divalproex Sodium | Divalproex Sodium | 127 | 27 |
| Buspirone Hcl | Buspirone Hcl | 124 | 25 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 123 | 20 |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 123 | 17 |
| Citalopram Hbr | Citalopram Hydrobromide | 118 | 20 |
| Prednisone | Prednisone | 117 | 71 |
| Myrbetriq | Mirabegron | 116 | 13 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 110 | 18 |
| Entresto | Sacubitril/Valsartan | 106 | 21 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 103 | 18 |
| Methocarbamol | Methocarbamol | 103 | 37 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 100 | 13 |
| Lamotrigine | Lamotrigine | 96 | suppressed |
| Nystatin | Nystatin | 96 | 59 |
| Nystop | Nystatin | 91 | 41 |
| Ondansetron Hcl | Ondansetron Hcl | 88 | 51 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 87 | 16 |
| Nifedipine Er | Nifedipine | 86 | 22 |
| Amiodarone Hcl | Amiodarone Hcl | 84 | 22 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 82 | 29 |
| Paroxetine Hcl | Paroxetine Hcl | 78 | 12 |
| Dicyclomine Hcl | Dicyclomine Hcl | 77 | 19 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 76 | 45 |
| Cephalexin | Cephalexin | 76 | 45 |
| Methenamine Hippurate | Methenamine Hippurate | 76 | suppressed |
| Bupropion Xl | Bupropion Hcl | 75 | 11 |
| Pregabalin | Pregabalin | 75 | 13 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 74 | 15 |
| Baclofen | Baclofen | 74 | 14 |
| Humalog Kwikpen U-100 | Insulin Lispro | 74 | 20 |
| Ropinirole Hcl | Ropinirole Hcl | 73 | 13 |
| Atenolol | Atenolol | 72 | 15 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 71 | 15 |
| Warfarin Sodium | Warfarin Sodium | 70 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 68 | 36 |
| Ezetimibe | Ezetimibe | 64 | 11 |
| Meloxicam | Meloxicam | 64 | 13 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 63 | 12 |
| Primidone | Primidone | 62 | suppressed |
| Olanzapine | Olanzapine | 61 | 14 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 61 | suppressed |
| Hydrocortisone | Hydrocortisone | 59 | 18 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 58 | 28 |
| Januvia | Sitagliptin Phosphate | 57 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 56 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 56 | 41 |
| Cefuroxime | Cefuroxime Axetil | 55 | 52 |
| Colchicine | Colchicine | 55 | 33 |
| Digoxin | Digoxin | 55 | 13 |
| Oxybutynin Chloride | Oxybutynin Chloride | 55 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 54 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 54 | 22 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 52 | 14 |
| Ipratropium Bromide | Ipratropium Bromide | 51 | 17 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 49 | 38 |
| Incruse Ellipta | Umeclidinium Bromide | 46 | suppressed |
| Metolazone | Metolazone | 46 | 12 |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 46 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 45 | 15 |
| Solifenacin Succinate | Solifenacin Succinate | 45 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 44 | suppressed |
| Tobramycin-Dexamethasone | Tobramycin/Dexamethasone | 44 | 31 |
| Divalproex Sodium Er | Divalproex Sodium | 43 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 42 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 41 | suppressed |
| Lumigan | Bimatoprost | 40 | suppressed |
| Celecoxib | Celecoxib | 39 | suppressed |
| Folic Acid | Folic Acid | 39 | suppressed |
| Novofine Autocover | Pen Needle, Diabetic, Safety | 39 | 13 |
| Meclizine Hcl | Meclizine Hcl | 38 | 19 |
| Metformin Hcl Er | Metformin Hcl | 38 | suppressed |
| Timolol Maleate | Timolol Maleate | 38 | 12 |
| Venlafaxine Hcl | Venlafaxine Hcl | 38 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 37 | suppressed |
| Ketoconazole | Ketoconazole | 37 | 14 |
| Mounjaro | Tirzepatide | 37 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 36 | 16 |
| Clonazepam | Clonazepam | 36 | suppressed |
| Dutasteride | Dutasteride | 36 | suppressed |
| Novolog Flexpen | Insulin Aspart | 36 | 15 |
| Ondansetron Odt | Ondansetron | 36 | 19 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 36 | suppressed |
| Ramipril | Ramipril | 36 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 34 | 30 |
| Breo Ellipta | Fluticasone/Vilanterol | 34 | suppressed |
| Topiramate | Topiramate | 34 | suppressed |
| Calcitriol | Calcitriol | 33 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 33 | 16 |
| Repaglinide | Repaglinide | 33 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 32 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 32 | suppressed |
| Carbamazepine | Carbamazepine | 32 | suppressed |
| Lovastatin | Lovastatin | 32 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 31 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 31 | suppressed |
| Rexulti | Brexpiprazole | 31 | suppressed |
| Sucralfate | Sucralfate | 31 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 30 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 30 | suppressed |
| Haloperidol | Haloperidol | 30 | suppressed |
| Ozempic | Semaglutide | 30 | suppressed |
| Brilinta | Ticagrelor | 29 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 29 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 29 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 29 | suppressed |
| Metronidazole | Metronidazole | 28 | 13 |
| Tizanidine Hcl | Tizanidine Hcl | 28 | suppressed |
| Amoxicillin | Amoxicillin | 27 | 16 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 27 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 27 | suppressed |
| Restasis | Cyclosporine | 27 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 26 | suppressed |
| Azithromycin | Azithromycin | 26 | 24 |
| Doxazosin Mesylate | Doxazosin Mesylate | 26 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 26 | suppressed |
| Nitroglycerin | Nitroglycerin | 26 | 19 |
| Rivastigmine | Rivastigmine Tartrate | 26 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 25 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 25 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 25 | suppressed |
| Fluconazole | Fluconazole | 25 | 16 |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 25 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 25 | 11 |
| Labetalol Hcl | Labetalol Hcl | 25 | suppressed |
| Letrozole | Letrozole | 25 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 25 | suppressed |
| Sotalol | Sotalol Hcl | 25 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 25 | 13 |
| Enulose | Lactulose | 24 | suppressed |
| Aripiprazole | Aripiprazole | 23 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 23 | 11 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 23 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 23 | 12 |
| Gemtesa | Vibegron | 23 | suppressed |
| Insulin Lispro | Insulin Lispro | 23 | suppressed |
| Linzess | Linaclotide | 23 | suppressed |
| Mupirocin | Mupirocin | 23 | 13 |
| Diazepam | Diazepam | 22 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 22 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 21 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 21 | 12 |
| Rytary | Carbidopa/Levodopa | 21 | suppressed |
| Calcium Acetate | Calcium Acetate | 20 | suppressed |
| Cilostazol | Cilostazol | 20 | suppressed |
| Clomipramine Hcl | Clomipramine Hcl | 20 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 20 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 19 | 19 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 19 | 11 |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 19 | suppressed |
| Fluphenazine Hcl | Fluphenazine Hcl | 19 | suppressed |
| Glimepiride | Glimepiride | 19 | suppressed |
| Sulfasalazine | Sulfasalazine | 19 | suppressed |
| Trulicity | Dulaglutide | 19 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Lactulose | Lactulose | 18 | 11 |
| Tiotropium Bromide | Tiotropium Bromide | 18 | suppressed |
| Ursodiol | Ursodiol | 18 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 17 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 17 | suppressed |
| Ibuprofen | Ibuprofen | 17 | 12 |
| Indapamide | Indapamide | 17 | suppressed |
| Heparin Sodium | Heparin Sodium,porcine | 16 | suppressed |
| Telmisartan | Telmisartan | 16 | suppressed |
| Hydroxyurea | Hydroxyurea | 15 | suppressed |
| Loperamide | Loperamide Hcl | 15 | 11 |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 15 | suppressed |
| Brinzolamide | Brinzolamide | 14 | suppressed |
| Chlorthalidone | Chlorthalidone | 14 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 14 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 14 | suppressed |
| Erythromycin | Erythromycin Base | 14 | suppressed |
| Fenofibrate | Fenofibrate | 14 | suppressed |
| Lansoprazole | Lansoprazole | 14 | suppressed |
| Nadolol | Nadolol | 14 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 14 | suppressed |
| Trospium Chloride | Trospium Chloride | 14 | suppressed |
| Acetazolamide | Acetazolamide | 13 | suppressed |
| Anagrelide Hcl | Anagrelide Hcl | 13 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Bimatoprost | Bimatoprost | 13 | suppressed |
| Brimonidine Tartrate-Timolol | Brimonidine Tartrate/Timolol | 13 | suppressed |
| Carbamazepine Er | Carbamazepine | 13 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 13 | suppressed |
| Levofloxacin | Levofloxacin | 13 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 13 | suppressed |
| Phenobarbital | Phenobarbital | 13 | suppressed |
| Premarin | Estrogens, Conjugated | 13 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 12 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 12 | suppressed |
| Dulera | Mometasone/Formoterol | 12 | suppressed |
| Galantamine Er | Galantamine Hbr | 12 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 12 | suppressed |
| Temazepam | Temazepam | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 12 | suppressed |
| Zonisamide | Zonisamide | 12 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 11 | suppressed |
| Azathioprine | Azathioprine | 11 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 11 | suppressed |
| Cyclosporine | Cyclosporine | 11 | suppressed |
| Enalapril-Hydrochlorothiazide | Enalapril/Hydrochlorothiazide | 11 | suppressed |
| Fosfomycin Tromethamine | Fosfomycin Tromethamine | 11 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 11 | suppressed |
| Lidocaine | Lidocaine | 11 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 11 | suppressed |
| Novofine 32 | Pen Needle, Diabetic | 11 | suppressed |
| Pioglitazone-Metformin | Pioglitazone Hcl/Metformin Hcl | 11 | suppressed |
| Procrit | Epoetin Alfa | 11 | suppressed |
| Trifluoperazine Hcl | Trifluoperazine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $177.97 · 9 records | Otsuka America Pharmaceutical, Inc. | BOTOX, MOUNJARO, REXULTI, TRELEGY ELLIPTA, TZIELD, Veozah, XIFAXAN, ZEPBOUND | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error